Core Viewpoint - 百心安-B's stock surged over 52% following the announcement of its Iberis RDN system receiving a five-year healthcare qualification in France, indicating strong market potential and positive clinical developments [1] Company Developments - 百心安's Iberis RDN system has been granted a five-year healthcare qualification by French authorities, with the possibility of renewal, enhancing its clinical application support in Europe [1] - The company has also secured clinical application and guideline recommendations in Italy, Germany, and Spain [1] - In July, media reports indicated that the U.S. CMS proposed to include RDN in the healthcare coverage for patients with uncontrolled hypertension [1] Market Performance - As of the latest report, 百心安-B's stock price reached 9.22 HKD, with a trading volume of 98.2961 million HKD, reflecting strong investor interest [1] - 中信建投 highlighted the significant and long-term effectiveness of RDN in lowering blood pressure, along with its simple procedure and low complication rates, suggesting a broad long-term market potential [1] Commercialization Progress - 百心安's Iberis RDN system completed its first commercial procedure in Germany in February this year, marking a significant milestone in its commercialization efforts [1] - The company is advancing the commercialization of its RDN products both domestically and internationally, with a focus on the results of its first year of commercialization in 2025 [1]
港股异动 | 百心安-B(02185)尾盘涨超52% 旗下RDN系统此前获法国5年报销许可 机构建议关注商业化成果